1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease.
[online]
, (2009).
2. Barnes, P. J. Emerging pharmacotherapies for COPD. Chest 134, 1278–1286 (2008).
3. Lipworth, B. J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365, 167–275 (2005).
4. Hatzelmann, A. & Schudt, C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297, 267–279 (2001).
5. Bundschuh, D. S. et al. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther. 297, 280–290 (2001).